COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

11.90 -0.05 (-0.42%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2 3 4 5 6 7 8 9

...

33 34 Next >

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 02, 2026

From Compass Pathfinder Limited

Via Business Wire

Compass Pathways Appoints Kelley Boucher as Chief People Officer

September 30, 2026

From Compass Pathfinder Limited

Via Business Wire

Compass Pathways Targets Q4 COMP360 NDA Completion, Eyes 2027 Launch ↗

September 24, 2026

Compass Pathways (NASDAQ:CMPS) executives said the company remains on track to complete its rolling New Drug Application submission for COMP360 in the fourth quarter, while preparing commercial...

Via MarketBeat

Topics Cannabis Government

Compass Pathways (NASDAQ:CMPS) Shares Plunge 42% After Q2 Report Despite Narrower-Than-Expected Loss ↗

August 05, 2026

Via Chartmill

Compass Pathways Targets 2027 COMP360 Launch After Positive Phase III Depression Data ↗

September 22, 2026

Compass Pathways (NASDAQ:CMPS) said it remains on track to complete its rolling New Drug Application submission for COMP360 in the fourth quarter of 2026, following positive Phase III studies of its...

Via MarketBeat

Topics Cannabis Government

Compass Pathways Eyes 2027 COMP360 Launch as FDA Review Advances ↗

September 22, 2026

Compass Pathways (NASDAQ:CMPS) expects to complete its new drug application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression, in the fourth quarter,...

Via MarketBeat

Topics Cannabis Government

Compass Pathways Eyes 2027 COMP360 Launch as FDA Filing Nears ↗

September 22, 2026

Compass Pathways (NASDAQ:CMPS) said it expects to complete its rolling New Drug Application submission for its synthetic psilocybin treatment, COMP360, in the fourth quarter and continues to target a...

Via MarketBeat

Topics Cannabis Government

Compass Pathways to Participate in TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026

September 16, 2026

From Compass Pathfinder Limited

Via Business Wire

Compass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 2026

September 15, 2026

From Compass Pathfinder Limited

Via Business Wire

Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training

September 10, 2026

From Compass Pathfinder Limited

Via Business Wire

Compass Pathways to Participate in Investor Conferences the Week of September 14th

September 10, 2026

From Compass Pathfinder Limited

Via Business Wire

Compass Pathways’ New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 Year

September 09, 2026

From Compass Pathfinder Limited

Via Business Wire

Compass Pathways to Debut U.S. HCP Education Campaign and Present New HEOR Data at Psych Congress 2026

September 08, 2026

From Compass Pathfinder Limited

Via Business Wire

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 03, 2026

From Compass Pathfinder Limited

Via Business Wire

Compass Pathways Recognized as a 2026 Fierce 50 Breakthrough Honoree

September 02, 2026

From Compass Pathfinder Limited

Via Business Wire

Compass Pathways to Participate in 2026 Cantor Global Healthcare Conference on September 9, 2026

September 01, 2026

From Compass Pathfinder Limited

Via Business Wire

COMPASS Pathways (CMPS) Q2 2026 Earnings Call Transcript ↗

August 12, 2026

COMP360 shows 39% response rate; commercial launch targeted for H1 2027.

Via The Motley Fool

Topics Earnings

Compass Pathways Targets 2027 COMP360 Launch as FDA Filing Advances ↗

August 12, 2026

Compass Pathways (NASDAQ:CMPS) said it remains on track to complete a new drug application for COMP360, its investigational psilocybin treatment for treatment-resistant depression, in the fourth...

Via MarketBeat

Topics Government

Compass Pathways to Participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026

August 06, 2026

From Compass Pathfinder Limited

Via Business Wire

Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin

August 06, 2026

From Compass Pathfinder Limited

Via Business Wire

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 05, 2026

From Compass Pathfinder Limited

Via Business Wire

A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 Readout

August 05, 2026

Issued on behalf of Helus Pharma (Nasdaq: HELP)

From USA News Group

Via GlobeNewswire

Compass Pathways Q2 Earnings Call Highlights ↗

August 05, 2026

Compass Pathways (NASDAQ:CMPS) said it remains on track to complete its new drug application, or NDA, filing for COMP360 in treatment-resistant depression in the fourth quarter of 2026, following...

Via MarketBeat

Topics Cannabis Earnings Government

Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights

August 05, 2026

From Compass Pathfinder Limited

Via Business Wire

Compass Pathways to Announce Second Quarter and First Half 2026 Financial Results on August 5, 2026

July 29, 2026

From Compass Pathfinder Limited

Via Business Wire

Eli Lilly Is Acquiring AtaiBeckley for $2.8 Billion. Cathie Wood Thinks Another Psychedelic Drug Stock Is an Even Better Bet. ↗

July 29, 2026

Cathie Wood is loading up on shares of a biotech that could be one of the first entrants to the psychedelics market.

Via The Motley Fool

Topics ETFs Government

Eli Lilly Is Acquiring a Psychedelic Medicine Biotech. Here's What You Need to Know. ↗

July 23, 2026

Lilly's purchase of AtaiBeckley is yet another strategic move in its bid to diversify its pipeline.

Via The Motley Fool

Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates

July 21, 2026

EQNX::TICKER_START (NASDAQ:HELP),(NASDAQ:CMPS),(NASDAQ:ATAI),(NYSE:JNJ),(NYSE:LLY) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Artificial Intelligence

Compass Pathways Announces Publication of Post-Hoc Analysis Demonstrating Distinction of COMP360 Trial Monitoring & Support from Psychotherapy

July 16, 2026

From Compass Pathfinder Limited

Via Business Wire

Compass Pathways Eyes 2027 Launch as Psilocybin Depression Data Holds Up ↗

July 10, 2026

Compass Pathways (NASDAQ:CMPS) said new 26-week data from its Phase 3 COMP006 trial further support the durability and safety profile of COMP360, its investigational psilocybin therapy for...

Via MarketBeat

Topics Cannabis Government

< Previous 1 2 3 4 5 6 7 8 9

...

33 34 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.